New facets of antifungal therapy
Journal
Virulence
Journal Volume
8
Journal Issue
2
Pages
222-236
Date Issued
2017
Author(s)
Abstract
Invasive fungal infections remain a major cause of morbidity and mortality in immunocompromised patients, and such infections are a substantial burden to healthcare systems around the world. However, the clinically available armamentarium for invasive fungal diseases is limited to 3 main classes (i.e., polyenes, triazoles, and echinocandins), and each has defined limitations related to spectrum of activity, development of resistance, and toxicity. Further, current antifungal therapies are hampered by limited clinical efficacy, high rates of toxicity, and significant variability in pharmacokinetic properties. New antifungal agents, new formulations, and novel combination regimens may improve the care of patients in the future by providing improved strategies to combat challenges associated with currently available antifungal agents. Likewise, therapeutic drug monitoring may be helpful, but its present use remains controversial due to the lack of available data. This article discusses new facets of antifungal therapy with a focus on new antifungal formulations and the synergistic effects between drugs used in combination therapy. ? 2017 Taylor & Francis.
Subjects
combination therapy; fungal pathogens; new antifungal formulations
SDGs
Other Subjects
amphotericin B; amphotericin B deoxycholate; amphotericin B lipid complex; anidulafungin; antifungal agent; caspofungin; fluconazole; flucytosine; isavuconazole; isavuconazonium; itraconazole; ketoconazole; micafungin; posaconazole; scy 078; unclassified drug; voriconazole; vt 1161; antifungal agent; echinocandin; polyene; triazole derivative; antifungal resistance; antifungal therapy; aspergillosis; candidiasis; coccidioidomycosis; combination chemotherapy; cryptococcosis; drug efficacy; drug monitoring; drug potentiation; drug safety; fungicidal activity; human; iatrogenic disease; immunocompromised patient; meta analysis (topic); mycosis; nonhuman; pharmacokinetic assay; phase 1 clinical trial (topic); phase 2 clinical trial (topic); prophylaxis; randomized controlled trial (topic); Review; systemic mycosis; Zygomycetes; chemistry; combination drug therapy; drug development; Invasive Fungal Infections; microbiology; Mycoses; Antifungal Agents; Drug Discovery; Drug Synergism; Drug Therapy, Combination; Echinocandins; Humans; Immunocompromised Host; Invasive Fungal Infections; Mycoses; Polyenes; Triazoles
Type
journal article